APLCC 2016
INSIGHT
APLCC 2016 | IASLC ASIA PACIFIC LUNG CANCER CONFERENCE
Prof Ball
Stereotactic Body Radiation Therapy
(SBRT), also known as stereotactic ablative
body radiotherapy (SABR), has been a
major development in treatment of lung
cancer in last few years. It holds the promise
of not only curing early stage operable non
small cell lung cancer (NSCLC) but doing so
with patient comfort and convenience; and
minimal toxicity.
SBRT is a course of very high dose radiation
treatment capable of sterilizing or getting
rid of the cancer with 1-5 abbreviated
doses over one to seven days, dramatically
Hosted by
Supported by
Platinum:
-1-
ENTERING THE
IMMUNOTHERAPY
ERA
In the past two decades, chemotherapy
and targeted therapy have established
their major milestones in lung cancer
management. Recently, the strong evidence
of checkpoint inhibitors has emerged as
the coming of immunotherapy era in
cancer therapy. This therapy promises to
be a groundbreaking new approach to lung
cancer. But this new science also poses new
questions: it works incredibly well for only
some of the patients, so identifying a robust
biomarker will be essential.
Silver:
ISSUE 2
(Continued from page 1: SBRT Holds The Promise Of Curing Early Stage NSCLC)
Prof Ball
There have been two randomized clinical trials in US and the Netherlands to
evaluate if using SBRT is as curative as surgery in early stage NSCLC which is
not near heart or major blood vessels or airway, but these trials had to be closed
prematurely due to slow accrual. Surgery has a well-established role dating
back decades for the management of early stage operable NSCLC and so some
patients may like to stick with surgery. On other hand some patients may opt out
of surgery because SBRT is painless (like an x-ray) and does not involve any
anaesthesia or the risks and dangers of surgery, and has minimal toxicity with
better patient comfort and convenience.
Unfortunately these clinical trials were too small to be conclusive and we need
further studies to be done advocated Prof Ball.
ISSUE 2
2nd & 3rd generation inhibitors reduced toxicity and Significant clinical activity is seen in about 25% of patients, or even
improved efficacy
higher if patients are selected for those with tumors over-expressing
When he started treating lung
cancer 25 years ago, there were
very few treatment options
available. Most patients of lung
cancer had no treatment at all.
Treatment options for lung cancer
back then were very toxic and not
very effective. About ten years
ago we discovered driver genetic
mutation that could be specifically
inhibited by drug and showed
dramatic responses in patients
in terms of improved symptoms
and prolonged survival. This was
a big revolution in lung cancer
therapy! Today we do not treat
non-small cell lung cancer
without knowing the genetic
profile of the patient. In last
couple of years we had the
introduction of new second and
third generation inhibitors for
these targets that have even better
efficacy and reduced toxicity for
lung cancer patients said Prof
David Carbone.
ISSUE 2
DR LAM KAI
SENG, Consultant
Clinical Oncologist,
Malaysia
DR LE HONG
MINH, Clinical
Oncologist,
Vietnam
-4-
ISSUE 2
DR WADE FANG,
Taiwan
DR YAO YINAN,
Lung Cancer
Researcher,
China
ISSUE 2
DEALING
WITH STAGE
IIIA N2 NON
SMALL CELL
LUNG CANCER
(NSCLC)
ensures that they do not have metastasis,
their N2 status is known and the size of
the tumour is in the stage IIIA or IIIB said
Dr Francoise Mornex, Professor of
Oncology at the University Claude Bernard
in Lyon, France. She is also the Chairman
of the Radiation Oncology Department in
Lyon, Centre Hospitalier Lyon Sud, and
member of Board of Directors of IASLC
and APLCC 2016 Committee.
ISSUE 2
extremely important to compare the results of the same trial designed in Asia with those in other
parts of the world, because it is important to have responses of different tumours and a precise
tolerance profile to these new agents, especially when combined with radiation.
Changing scenario
Dr Mornex shared that,
Dr Francoise Mornex
-7-
ISSUE 2
Dr Tetsuya Mitsudomi
Member APLCC 2016 International Committee and former
Member, Board of Directors, IASLC
President, Japanese Lung Cancer Society (JLCS)
Professor, Thoracic Surgery, Kindai University Faculty of
Medicine, Japan
Dr David R Gandara
Editor-in-Chief, Clinical Lung Cancer
Director, Thoracic Oncology Program; Professor and Senior
Advisor to Director, UC Davis Comprehensive Cancer Center, USA
Treasurer and member Board of Dirers, IASLC
Twitter: @APLCC2016
Twitter conference hashtag: #APLCC2016
Facebook.com/APLCC2016
Check www.aplcc2016.com for conference updates!
Hosted by
Supported by
Conference Secretariat
Platinum:
Gold:
Silver:
-8-